Use of a Novel Ultrafiltration Device as a Treatment Strategy for Diuretic Resistant, Refractory Heart Failure

Initial Clinical Experience in a Single Center

Kelly V. Liang, Ann R. Hiniker, Amy W. Williams, Barry L. Karon, Eddie L. Greene, Margaret May Redfield

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: The System 100 UF device allows ultrafiltration (UF) via peripheral access and is approved for use in heart failure (HF), although clinical trials defining optimal target population and clinical utility are lacking. We report our initial experience with clinical use of this system in very advanced, diuretic resistant HF patients. Methods and Results: Eleven HF patients (mean age 70 years) underwent 1 to 5 UF treatments each (total 32 UF). The goal was to remove 4 liters of fluid per 8-hour UF. Baseline creatinine averaged 2.2 mg/dL (range .9-3.2) while estimated glomerular filtration rates (GFRs) averaged 38 mL/min (range 20-87). Nine patients (82%) had moderate (GFR 30-59; n = 3) or severe (GFR <30; n = 6) renal dysfunction. Nine patients (82%) had documented right ventricular dysfunction, 6 with severe tricuspid regurgitation. Average daily intravenous furosemide dose prior to UF was 258 mg (range 80-480). Patients had received nesiritide (n = 4), dopamine (n = 4), and zaroxylyn (n = 7) prior to UF. Of the 32 UF treatments, 13 (41%) removed >3500 mL, 11 (34%) removed 2500-3500 mL, and 8 (25%) removed <2500 mL. Only one UF treatment (3%) was aborted due to hypotension. There were no significant complications related to UF. Five patients (45%) experienced an increase in creatinine of >.3 mg/dl. Five patients required dialysis for persistant diuretic resistant volume overload or uremic symptoms. Six-month mortality was 55%. Conclusions: Peripheral UF safely but variably removed fluid. In this very high-risk, advanced HF population, 45% of patients developed worsening renal function during UF therapy. Controlled studies are needed to determine the impact of UF on renal function and outcomes in high-risk populations such as this.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalJournal of Cardiac Failure
Volume12
Issue number9
DOIs
StatePublished - Dec 2006

Fingerprint

Ultrafiltration
Diuretics
Heart Failure
Equipment and Supplies
Glomerular Filtration Rate
Therapeutics
Kidney
Health Services Needs and Demand
Population
Dialysis
Creatinine
Clinical Trials
Mortality

Keywords

  • Heart failure
  • Renal failure
  • Ultrafiltration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Use of a Novel Ultrafiltration Device as a Treatment Strategy for Diuretic Resistant, Refractory Heart Failure : Initial Clinical Experience in a Single Center. / Liang, Kelly V.; Hiniker, Ann R.; Williams, Amy W.; Karon, Barry L.; Greene, Eddie L.; Redfield, Margaret May.

In: Journal of Cardiac Failure, Vol. 12, No. 9, 12.2006, p. 707-714.

Research output: Contribution to journalArticle

@article{8b2a07306df64bbf8a611d0f8e00f746,
title = "Use of a Novel Ultrafiltration Device as a Treatment Strategy for Diuretic Resistant, Refractory Heart Failure: Initial Clinical Experience in a Single Center",
abstract = "Background: The System 100 UF device allows ultrafiltration (UF) via peripheral access and is approved for use in heart failure (HF), although clinical trials defining optimal target population and clinical utility are lacking. We report our initial experience with clinical use of this system in very advanced, diuretic resistant HF patients. Methods and Results: Eleven HF patients (mean age 70 years) underwent 1 to 5 UF treatments each (total 32 UF). The goal was to remove 4 liters of fluid per 8-hour UF. Baseline creatinine averaged 2.2 mg/dL (range .9-3.2) while estimated glomerular filtration rates (GFRs) averaged 38 mL/min (range 20-87). Nine patients (82{\%}) had moderate (GFR 30-59; n = 3) or severe (GFR <30; n = 6) renal dysfunction. Nine patients (82{\%}) had documented right ventricular dysfunction, 6 with severe tricuspid regurgitation. Average daily intravenous furosemide dose prior to UF was 258 mg (range 80-480). Patients had received nesiritide (n = 4), dopamine (n = 4), and zaroxylyn (n = 7) prior to UF. Of the 32 UF treatments, 13 (41{\%}) removed >3500 mL, 11 (34{\%}) removed 2500-3500 mL, and 8 (25{\%}) removed <2500 mL. Only one UF treatment (3{\%}) was aborted due to hypotension. There were no significant complications related to UF. Five patients (45{\%}) experienced an increase in creatinine of >.3 mg/dl. Five patients required dialysis for persistant diuretic resistant volume overload or uremic symptoms. Six-month mortality was 55{\%}. Conclusions: Peripheral UF safely but variably removed fluid. In this very high-risk, advanced HF population, 45{\%} of patients developed worsening renal function during UF therapy. Controlled studies are needed to determine the impact of UF on renal function and outcomes in high-risk populations such as this.",
keywords = "Heart failure, Renal failure, Ultrafiltration",
author = "Liang, {Kelly V.} and Hiniker, {Ann R.} and Williams, {Amy W.} and Karon, {Barry L.} and Greene, {Eddie L.} and Redfield, {Margaret May}",
year = "2006",
month = "12",
doi = "10.1016/j.cardfail.2006.08.210",
language = "English (US)",
volume = "12",
pages = "707--714",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "9",

}

TY - JOUR

T1 - Use of a Novel Ultrafiltration Device as a Treatment Strategy for Diuretic Resistant, Refractory Heart Failure

T2 - Initial Clinical Experience in a Single Center

AU - Liang, Kelly V.

AU - Hiniker, Ann R.

AU - Williams, Amy W.

AU - Karon, Barry L.

AU - Greene, Eddie L.

AU - Redfield, Margaret May

PY - 2006/12

Y1 - 2006/12

N2 - Background: The System 100 UF device allows ultrafiltration (UF) via peripheral access and is approved for use in heart failure (HF), although clinical trials defining optimal target population and clinical utility are lacking. We report our initial experience with clinical use of this system in very advanced, diuretic resistant HF patients. Methods and Results: Eleven HF patients (mean age 70 years) underwent 1 to 5 UF treatments each (total 32 UF). The goal was to remove 4 liters of fluid per 8-hour UF. Baseline creatinine averaged 2.2 mg/dL (range .9-3.2) while estimated glomerular filtration rates (GFRs) averaged 38 mL/min (range 20-87). Nine patients (82%) had moderate (GFR 30-59; n = 3) or severe (GFR <30; n = 6) renal dysfunction. Nine patients (82%) had documented right ventricular dysfunction, 6 with severe tricuspid regurgitation. Average daily intravenous furosemide dose prior to UF was 258 mg (range 80-480). Patients had received nesiritide (n = 4), dopamine (n = 4), and zaroxylyn (n = 7) prior to UF. Of the 32 UF treatments, 13 (41%) removed >3500 mL, 11 (34%) removed 2500-3500 mL, and 8 (25%) removed <2500 mL. Only one UF treatment (3%) was aborted due to hypotension. There were no significant complications related to UF. Five patients (45%) experienced an increase in creatinine of >.3 mg/dl. Five patients required dialysis for persistant diuretic resistant volume overload or uremic symptoms. Six-month mortality was 55%. Conclusions: Peripheral UF safely but variably removed fluid. In this very high-risk, advanced HF population, 45% of patients developed worsening renal function during UF therapy. Controlled studies are needed to determine the impact of UF on renal function and outcomes in high-risk populations such as this.

AB - Background: The System 100 UF device allows ultrafiltration (UF) via peripheral access and is approved for use in heart failure (HF), although clinical trials defining optimal target population and clinical utility are lacking. We report our initial experience with clinical use of this system in very advanced, diuretic resistant HF patients. Methods and Results: Eleven HF patients (mean age 70 years) underwent 1 to 5 UF treatments each (total 32 UF). The goal was to remove 4 liters of fluid per 8-hour UF. Baseline creatinine averaged 2.2 mg/dL (range .9-3.2) while estimated glomerular filtration rates (GFRs) averaged 38 mL/min (range 20-87). Nine patients (82%) had moderate (GFR 30-59; n = 3) or severe (GFR <30; n = 6) renal dysfunction. Nine patients (82%) had documented right ventricular dysfunction, 6 with severe tricuspid regurgitation. Average daily intravenous furosemide dose prior to UF was 258 mg (range 80-480). Patients had received nesiritide (n = 4), dopamine (n = 4), and zaroxylyn (n = 7) prior to UF. Of the 32 UF treatments, 13 (41%) removed >3500 mL, 11 (34%) removed 2500-3500 mL, and 8 (25%) removed <2500 mL. Only one UF treatment (3%) was aborted due to hypotension. There were no significant complications related to UF. Five patients (45%) experienced an increase in creatinine of >.3 mg/dl. Five patients required dialysis for persistant diuretic resistant volume overload or uremic symptoms. Six-month mortality was 55%. Conclusions: Peripheral UF safely but variably removed fluid. In this very high-risk, advanced HF population, 45% of patients developed worsening renal function during UF therapy. Controlled studies are needed to determine the impact of UF on renal function and outcomes in high-risk populations such as this.

KW - Heart failure

KW - Renal failure

KW - Ultrafiltration

UR - http://www.scopus.com/inward/record.url?scp=33845410110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845410110&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2006.08.210

DO - 10.1016/j.cardfail.2006.08.210

M3 - Article

VL - 12

SP - 707

EP - 714

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 9

ER -